Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ganciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.44 |
| ▸ | EDNRA known ✓ | P25101 | 1/20 | 0.38 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | VCP | P55072 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.40 |
| ▸ | CDK2 | P24941 | 5/20 | 0.40 |
| ▸ | CDK1 | P06493 | 3/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganciclovir SCHEMBL29588756 | 1.00 | BLM (0.58) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL9123481 | 0.85 | BLM (0.62) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL14491348 | 0.84 | BLM (0.60) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ammonia Solution, Strong SCHEMBL10907047 | 0.84 | BLM (0.60) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Ganciclovir SCHEMBL15567856 | 0.83 | BLM (0.71) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL9583145 | 0.83 | MEN1 (0.62) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL10405635 | 0.82 | BLM (0.56) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL9583704 | 0.81 | MEN1 (0.57) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL10404919 | 0.81 | BLM (0.57) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL10404915 | 0.81 | BLM (0.57) | BLMMEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075696-A | Application of MSR1 inhibitor in preparation of anti-tumor immunopotentiator | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3443964-A1 | ANTIVIRAL FORMULATIONS | 3B Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9144576-B2 | Topical antiviral formulations | 3B PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| EP-2782585-A1 | ANTIVIRAL FORMULATIONS | 3B Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140221297-A1 | TOPICAL ANTIVIRAL FORMULATIONS | 3B PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130150312-A1 | TOPICAL ANTIVIRAL FORMULATIONS | 3B PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013077881-A1 | ANTIVIRAL FORMULATIONS | 3B PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-8236768-B2 | Topical antiviral formulations | 3B PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120058959-A1 | TOPICAL ANTIVIRAL FORMULATIONS | VIRAVERT LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |